Ocugen

OCGN

Market cap $437M

Overview Fund Activity

1.40 USD

+0.08

6.06%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

1.38

-0.02

1.43%

1 day

6.06%

5 days

32.08%

1 month

34.62%

3 months

28.44%

6 months

171.16%

Year to date

55.56%

1 year

25%

5 years

293.26%

10 years

-99.61%

About: Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Employees: 95

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

172% more call options, than puts

Call options by funds: $797K | Put options by funds: $293K

21% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 24

5% less funds holding

Funds holding: 109 [Q1] → 104 (-5) [Q2]

7% less capital invested

Capital invested by funds: $54.2M [Q1] → $50.2M (-$3.93M) [Q2]

8.52% less ownership

Funds ownership: 26.27% [Q1] → 17.75% (-8.52%) [Q2]

13% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 38

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

400% upside

Avg. target

$7

400% upside

High target

$7

400% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Daniil Gataulin	$7	Buy Maintained	4 Aug 2025
HC Wainwright & Co. Swayampakula Ramakanth	$7	Buy Reiterated	24 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about OCGN published over the past 30 days

The Motley Fool

Why Ocugen Stock Zoomed 12% Higher Today

On Monday, investors clearly saw excellent value in the stock of Ocugen (OCGN 12.15%), a biotech that concentrates on treatments for eye disorders. They traded the company's shares up by more than 12%, on the back of a fresh licensing agreement signed with a peer in Asia.

Why Ocugen Stock Zoomed 12% Higher Today

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. OCGN shares traded higher on Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., (“Kwangdong”) one of the leading pharmaceutical companies in Korea, for the exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP).

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled “The FDA Gauntlet: Strategies for a Successful Run at Approval” during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany.

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Zacks Investment Research

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the ongoing pivotal confirmatory OCU410ST Phase 2/3 GARDian3 clinical trial for Stargardt disease and provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA).

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company's common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company's common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

The Motley Fool

Ocugen (OCGN) Q2 Revenue Jumps 20%

Ocugen (OCGN) Q2 Revenue Jumps 20%

Ocugen (OCGN) Q2 Revenue Jumps 20%

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Ocugen, Inc. (NASDAQ:OCGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar - Chief Medical Officer Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Shankar Musunuri - Co-Founder, CEO & Chairman Tiffany J. Hamilton - AVP & Head of Corporate Communications Conference Call Participants Boris Peaker - Unidentified Company Daniil V.

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™